Clinical Study

Sl03-Ohd-102- Phase 1 Dose Escalation Study Of The Agonist Redirected Checkpoint, Sl-172154 (Sirpα-Fc-Cd40l), Administered Intratumorally In Subjects With Cutaneous Squamous Cell Carcinoma Or Squamous Cell Carcinoma Of The Head And Neck

Posted Date: Jan 18, 2021

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous squamous cell carcinoma (CSCC) or squamous cell carcinoma of the head and neck (SCCHN). The primary outcomes measured will be the maximum tolerated dosage and the incidences of adverse events.


To Be Eligible: Must Have Histologically Confirmed Diagnosis Of An Unresectable Or Recurrent, Locally Advanced Or Metastatic Cutaneous Squamous Cell Carcinoma Or Squamous Cell Carcinoma Of The Head And Neck, Ecog 0-1, Life Expectancy >12 Weeks, Adequate Organ Function, No Autoimmune Disease, No Other Concurrent Maligancy, No Hypersensitivity To Study Drugs/Components, No Other Significant Medical History Or Active Infection That May Impact Safety On Study


Hnscc, Head And Neck Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.